Fetal sex alters maternal anti-Mullerian hormone during pregnancy in cattle

Is serum AMH a suitable biomarker to determine litter size or fetal sex in goats?: A preliminary study

This study was conducted in Damascus goats to i) investigate the relationship between serum AMH concentrations and litter size, ii) evaluate the change in serum AMH concentration between the 35th and 135th days of pregnancy, iii) determine whether fetal sex affected the maternal AMH level. Estrus was synchronized in 110 goats (intravaginal sponge containing medroxyprogesterone acetate for nine days, combined with d-cloprostenol and Pregnant Mare Serum Gonadotropin at sponge removal). Blood samples were taken on the 4th and 9th days of synchronization. Goats at estrus were mated naturally. Study groups were established based on the number of fetuses on ultrasound examination as Group I (n = 18, goats carrying one fetus) and Group II (n = 18, goats carrying multiple fetuses) (Experiment I). Additionally, blood samples were taken every 20 days between the 35th and 135th days of pregnancy. After the parturition, groups were formed according to the sex of the kids; single/multiple male fetuses (GroupM, n = 8), single/multiple female fetuses (GroupF, n = 8), and fetuses of the opposite sex (GroupFM, n = 8), (Experiment II). There was no significant relationship between serum AMH concentration and litter size (P > 0.05). As pregnancy progressed maternal AMH concentration tended to decrease (P < 0.001), and fetal sex did not affect maternal AMH (P > 0.05). In conclution circulating AMH was not an ideally biomarker for determining litter size on natural breeding or predicting fetal sex in goats. Futher studies with larger sample sizes and the reduced individual variables (age and ovarian activity) are recommened.

Anti-Müllerian Hormone Concentrations Can Be Reliably Determined by a Single Measurement, Irrespective of Cycle, in Synchronised Ewes During Non-Breeding Season

Improvement of yield characteristics in animal breeding is important in terms of increasing animal production and sustainability. Fertility is one of the most important yield traits affecting economic gain in sheep breeding. Anti-Müllerian Hormone (AMH) is widely recognised as a dependable biomarker for assessing ovarian reserves and fertility potential. The aim of this study was to evaluate the dynamics of AMH during different phases of the sexual cycle in Norduz ewes the non-breeding season. Additionally, the study sought to assess the effects of age and body condition score (BCS) on AMH concentrations during these phases. A total of 32 Norduz ewes with a body condition score (BCS) of 3-4.5 and aged between 2 and 4 years were used as animal material in the study. All experimental procedures were carried out outside the breeding season and when the ewes were lactating. In all ewes in anestrus, intravaginal sponges (Esponjavet, 60 mg MAP, Hipra, Turkey) were kept in the vagina for 7 days for estrus synchronisation. Intramuscular injections of PMSG (Oviser, 500 IU, Hipra, Turkey) and PGF2α analog (Gestavet, 50 μg, Hipra, Turkey) were administered 48 h prior to sponge removal. Twenty-four hours after sponge removal, ewes were exposed to the ram for estrus detection. Since 5 ewes did not show estrus, blood samples were collected regularly from animals (n = 27) in which estrus was detected at three different stages: one just before the insertion of vaginal sponges (anestrus), another when heat was detected exposing to the ram (estrus), and the final one 10 days after estrus (diestrus). The serum samples were assessed for the levels of AMH and progesterone through the electrochemiluminessence immunoassay technique (ECLIA). The results of the analyses showed that serum AMH concentration did not vary between anestrus, estrus and diestrus phases of the sexual cycle of Norduz ewes outside the breeding season (p > 0.05). Furthermore, age and BCS had no effect on progesterone and AMH levels in different phases of the sexual cycle (p > 0.05). In conclusion, this study shows that serum AMH levels are constant at any stage of the estrus cycle. This suggests that phenotypic evaluation of ewes can be performed with a single measurement and that AMH is a reproducible and dependable biomarker that can be measured at any stage of the estrus cycle at an arbitrary time point.

Age-specific analysis of anti-müllerian hormone and liver biochemical parameters in freemartin holstein calves and heifers: A pilot study

Freemartinism is the most common congenital anomaly among sexual disorders in dairy cows. This syndrome typically occurs in different-sex twin pregnancies and causes vascular anastomoses to form with the placenta in the early stages of fetal development. The study aims to determine the effectiveness of Anti-müllerian hormone (AMH) levels in calves and heifers of different age groups for diagnostic factors and to investigate the potential consequences of different hormone levels in different age groups on some liver biochemical parameters. The study involved 50 cattle from diverse age categories, divided into the freemartin group (FM Group, n=25) and the control group (C Group, n=25). Both FM and control groups were further divided into early-age (3-5 months), middle-aged (5-9 months), and older-aged groups (9-12 months). Serum AMH levels, along with total protein, albumin, and total cholesterol levels, were measured. While no statistically significant difference in AMH levels was observed in the early-age group (P:0.53), significant differences were determined in the middle (P:0.015) and older-age groups (P:0.01), where the FM group exhibited significantly decreased AMH levels compared to the control group. The evaluation of liver biochemistry revealed a statistically significant difference in total protein levels between the FM and control groups in the older age group (P:0.033). Consequently, it is reasonable to suggest that AMH levels may serve as a valid parameter for diagnosing freemartin syndrome in calves aged older than five months. Conversely, particularly in young calves, no significant differences in liver functionality were observed between freemartin-affected and healthy calves.

Anti-Müllerian hormone: A novel biomarker for detecting bovine freemartinism

The anti-Müllerian hormone (AMH) indicates ovarian reserve in cattle, maintaining a consistent trajectory post-puberty. In heterosexual pregnancies, the development of the Müllerian duct in female foetuses is inhibited, resulting in an anticipated minimal or absent ovarian reserve capacity. This investigation aimed to compare AMH levels in healthy Holstein heifers that had reached puberty with those of freemartin animals of the same breed and age. The study incorporated Holstein heifers reaching puberty between 11 and 15 months of age in Group 1 (G1, n = 20) and freemartin animals in Group 2 (G2, n = 19, 16). AMH measurements (AMH-1/AMH-2) were recorded at 12-day intervals for the study participants. Notably, AMH levels in three freemartin animals could not be detected, prompting statistical analysis based on measurements from the remaining 16 freemartin animals in G2. A statistically significant correlation was observed between two separate measurements in G1 and G2 (p < .001). Furthermore, AMH-1 and AMH-2 levels were statistically higher in G1 than in G2 (p < .001). In G1, AMH-1 levels ranged from 227 to 677 pg/mL, with an average of 367.3 ± 25.5 pg/mL, and AMH-2 levels ranged from 234 to 645 pg/mL, with an average of 380.8 ± 24.4 pg/mL. Conversely, in G2, AMH-1 levels ranged from 10 to 72 pg/mL, with an average of 26.8 ± 4.44 pg/mL, and AMH-2 levels ranged from 12 to 68 pg/mL, with an average of 28.75 ± 4.18 pg/mL. The mean AMH levels in G1 were approximately 14 times higher than in G2 (p < .001). Consequently, ROC analysis utilizing AMH-1 and AMH-2 data established cut-off values of ≤72 and ≤ 68 pg/mL respectively for distinguishing freemartin animals. In conclusion, AMH could be used as a reliable biomarker for identifying Holstein freemartin animals.

Evaluation of serum anti-Müllerian hormone (AMH) and equine chorionic gonadotrophin (eCG) concentrations in pregnant mares in relation to foetal sex

The aim of this study was to investigate the foetal sex related difference and progression in maternal serum anti-Müllerian hormone (AMH) and equine chorionic gonadotrophin (eCG) concentrations during different points of time in pregnant Arabian mares. The study groups formed by 12 healthy male offspring- and 12 healthy female offspring-foaling mares, designated as group MFM and group FFM, respectively. Peripheral blood samples were collected on the day of natural mating and then monthly until the 6th month (mo) of gestation. Serum AMH was measured in all serum samples; eCG was measured in samples collected from 2 to 5 months Of gestation. Serum AMH concentrations of group FFM at mo 4 and mo 5 (3.89 ± 0.49 ng/ml; 2.89 ± 0.32 ng/ml), were significantly higher than in group MFM (2.11 ± 0.46 ng/ml; 1.87 ± 0.32 ng/ml), (P < 0.05). The mo of gestation (mo 1–6) had no effect on serum AMH concentrations of either group MMF or FFM (P > 0.05). Serum eCG concentrations of group FFM at mo 2 (359.73 ± 41.51 mIU/ml), were significantly higher than in group MFM (255 ± 21.18 mIU/ml) (P < 0.05). Group-time interaction for eCG concentrations at mo 2–4 was non-significant (P > 0.05). Concentrations of serum AMH showed no relationship with corresponding eCG levels at mo 2–4 (P > 0.05). Individual variations in AMH and eCG concentrations and the inability to determine a cut-off point for determination of foetal sex make these hormones unlikely candidates for determining foetal sex in the mare.

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women. It is characterized by chronic anovulation, hyperandrogenism, and the presence of polycystic ovary in ultrasound examination. PCOS is specified by an increased number of follicles at all growing stages, mainly seen in the preantral and small antral follicles and an increased serum level of Anti-Müllerian Hormone (AMH). Because of the strong correlation between circulating AMH levels and antral follicle count on ultrasound, Anti-Müllerian Hormone has been proposed as an alternative marker of ovulatory dysfunction in PCOS. However, the results from the current literature are not homogeneous, and the specific threshold of AMH in PCOS and PCOM is, therefore, very challenging. This review aims to update the current knowledge about AMH, the pathophysiology of AMH in the pathogenesis of PCOS, and the role of Anti-Müllerian Hormone in the treatment of this syndrome.

Fetal sex and maternal postpartum depressive symptoms: findings from two prospective pregnancy cohorts

BACKGROUND

Fetal sex is known to modify the course and complications of pregnancy, with recent evidence of sex-differential fetal influences on the maternal immune and endocrine systems. In turn, heightened inflammation and surges in reproductive hormone levels associated with pregnancy and parturition have been linked with the development of perinatal depression. Here, we examined whether there is an association between fetal sex and maternal depression assessed during the prenatal and postnatal periods.

METHODS

The study included two multi-ethnic, prospective pregnancy cohorts that enrolled women from prenatal clinics in the Northeastern United States between 2001 and 2018. Maternal depressive symptoms were measured during the prenatal and postnatal periods using the Edinburgh Postpartum Depression Scale (EPDS), and newborn sex was reported by the mother following delivery. We used logistic regression to examine associations between fetal sex and maternal depressive symptoms (EPDS > 10) during the prenatal period only, postnatal period only, or both periods versus no depressive symptoms during either period. We considered both unadjusted models and models adjusted for a core set of sociodemographic and lifestyle variables.

RESULTS

In adjusted models using PRISM data (N = 528), women pregnant with a male versus female fetus had significantly greater odds of depressive symptoms during the postnatal period compared to women without depressive symptoms during either period (odds ratio [OR] = 5.24, 95% confidence interval [CI] = 1.93, 14.21). The direction of results was consistent in the ACCESS cohort, although the findings did not reach statistical significance (OR = 2.05, 95% CI = 0.86, 4.93). Significant associations were not observed in either cohort among women with prenatal symptoms only or women with prenatal and postnatal symptoms.

CONCLUSIONS

Male fetal sex was associated with the onset of depressive symptoms during the postnatal period.

Reproductive Outcomes and Endocrine Profile in Artificially Inseminated versus Embryo Transferred Cows

Simple Summary

Bovine embryos are nowadays produced in laboratories, frozen and transferred to other cows. However, the percentage of pregnancies obtained after these transfers as well as difficulties found during labor, especially due to increased size of calves, are a matter of great concern. One of the possible explanations for these problems relies on the embryo being produced in in vitro conditions (laboratory settings), more specifically the culture medium (liquid) used to develop these embryos. In an attempt to better mimic what happens naturally, female reproductive liquids (from oviducts and uterus) were used as a supplement to the culture of the embryos. As controls, embryos produced using the standard protocol in the laboratory were produced, as well as embryos derived from artificial insemination of cows (in vivo). An evaluation on the pregnancy rates, how the hormonal profile of the recipients changed during pregnancy, difficulties during parturitions, and phenotype of calves were recorded. Results showed that all the groups were very similar, but many differences were noted on the hormonal profiles during pregnancy. In conclusion, all systems provided safe production of calves, but long-term analysis of these calves is necessary to understand the future impact of the laboratory protocols.

Abstract

The increasing use of in vitro embryo production (IVP) followed by embryo transfer (ET), alongside with cryopreservation of embryos, has risen concerns regarding the possible altered pregnancy rates, calving or even neonatal mortality. One of the hypotheses for these alterations is the current culture conditions of the IVP. In an attempt to better mimic the physiological milieu, embryos were produced with female reproductive fluids (RF) as supplements to culture medium, and another group of embryos were supplemented with bovine serum albumin (BSA) as in vitro control. Embryos were cryopreserved and transferred while, in parallel, an in vivo control (artificial insemination, AI) with the same bull used for IVP was included. An overview on pregnancy rates, recipients’ hormonal levels, parturition, and resulting calves were recorded. Results show much similarity between groups in terms of pregnancy rates, gestation length and calves’ weight. Nonetheless, several differences on hormonal levels were noted between recipients carrying AI embryos especially when compared to BSA. Some calving issues and neonatal mortality were observed in both IVP groups. In conclusion, most of the parameters studied were similar between both types of IVP derived embryos and the in vivo-derived embryos, suggesting that the IVP technology used was efficient enough for the safe production of calves.

Overview of Anti-Müllerian hormone (AMH) and association with fertility in female cattle

Anti-Müllerian hormone (AMH) is produced by granulosa cells of early-antral follicles found on the ovary. After production, it enters circulation and can be detected from a blood sample with an ELISA. Multiple works have found that circulating AMH is a reliable marker of the antral follicle population (AFP) of an animal as well as directly correlated to an animal's response to a superovulation protocol. Research has also found high repeatability within an animal's oestrous cycle. Further use of AMH may be valuable as a reproductive management tool, based on previous research linking productive life with circulating AMH in heifers and success to various breeding protocols by AMH concentration. The aim of this review was to summarize previous works describing basic function of AMH as well as explore recent research examining AMH as a reproductive tool and measurement of fertility in dairy animals.

A pilot longitudinal study of anti-Müllerian hormone levels throughout gestation in low risk pregnancy

BACKGROUND

Anti-Mϋllerian hormone (AMH) plays an important role regulating ovarian sensitivity to follicle-stimulating hormone and luteinizing hormone in folliculogenesis. Anti-Mϋllerian hormone is well established as a biomarker of ovarian reserve but may also have utility in predicting pregnancy outcomes. Few studies have described AMH levels in pregnancy and, among those that have, most have used cross-sectional study designs and are limited to participants seeking fertility treatment. Our aim was to analyze AMH longitudinally in low-risk pregnancies.

METHODS

We conducted a prospective cohort study at Baystate Medical Center, a large tertiary care hospital in Springfield, MA, USA. We recruited women (n = 30) with low risk, singleton pregnancies, aged 18 to 35 years, with BMI between 18 and 40 kg/m2, and without preexisting disease. Anti-Mϋllerian hormone (pmol/L) was measured in plasma samples collected at 5 prenatal care visits throughout gestation.

RESULTS

Anti-Mϋllerian hormone levels varied significantly over gestation (Friedman's analysis of variance, P value < .0001). At gestational weeks 7 to 10, average AMH was 36.7 pmol/L (standard error = 8.1) and at weeks 34 to 37 was 9.5 pmol/L (standard error = 1.9). Initial AMH varied between women, and an overall significant log-linear decline was observed.

CONCLUSIONS

Anti-Mϋllerian hormone varies between women and declines exponentially during pregnancy. The biological mechanism of the heterogeneity of AMH decline over gestation is unclear. Future studies evaluating AMH throughout pregnancy that also assess gravid health and pregnancy outcomes are warranted.